Innovative therapeutic approaches targeting inflammatory and intracellular signaling pathways involved in aPL mediated pathogenic effects have also been shown to be effective in managing non-criteria manifestations of APS and CAPS, as well as refractory obstetrical complications. The gene discussed is FASLG; the disease is autoimmune polyendocrinopathy.